Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms.
The main objective of this study is to establish a biological collection to evaluate the genomic profiling of leukemic cells from primary blasts at diagnosis and/or relapse to improve identification of the main genetic hits involved in resistance and could predict a high risk of relapse. Other objectives include the study of bone marrow mesenchymal stem cells and ex vivo drug testing.
0-25 years old
Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or
Relapsed or refractory AML or
Patients with genetic predisposition to develop AML or
Refuse to participate
Chronic myeloid leukemia (CML)
Lack of health insurance (French social security)
Under protection (tutelle, curatelle or sauvegarde de justice)